ストックスクリーナーアプリを入手
14.93
0.20%
0.03
プレマーケット:
15.00
0.07
+0.47%
前日終値:
$14.90
開ける：
$15
24時間の取引高:
1.51M
Relative Volume:
1.39
時価総額：
$686.97M
収益：
$159.01M
当期純損益:
$-21.72M
株価収益率:
-28.71
EPS:
-0.52
ネットキャッシュフロー:
$-20.63M
1週間 パフォーマンス:
+7.41%
1か月 パフォーマンス:
+27.93%
6か月 パフォーマンス:
-17.65%
1年 パフォーマンス:
+35.48%
1日の値動き範囲:
$14.72
$15.11
1週間の範囲:
$13.75
$15.11
52週間の値動き範囲:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
AXGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
14.93 | 685.59M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-17 | 開始されました | Lake Street | Buy |
| 2024-07-01 | 開始されました | Raymond James | Outperform |
| 2022-11-11 | 再開されました | Jefferies | Buy |
| 2022-05-09 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | Guggenheim | Buy |
| 2020-06-16 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-05-07 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-08-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | 開始されました | Canaccord Genuity | Buy |
| 2018-03-02 | 繰り返されました | Lake Street | Buy |
| 2018-01-05 | 再開されました | Cantor Fitzgerald | Overweight |
| 2017-11-30 | 開始されました | Jefferies | Buy |
| 2017-11-21 | 繰り返されました | Lake Street | Buy |
| 2017-07-31 | 開始されました | Leerink Partners | Outperform |
| 2017-06-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-03-06 | 開始されました | ROTH Capital | Buy |
| 2016-11-22 | アップグレード | Lake Street | Hold → Buy |
| 2016-11-07 | 繰り返されました | Wedbush | Outperform |
| 2016-11-03 | ダウングレード | Lake Street | Buy → Hold |
| 2016-08-04 | 繰り返されました | Wedbush | Outperform |
| 2014-05-14 | 開始されました | Dawson James | Buy |
| 2013-10-31 | 繰り返されました | Ladenburg Thalmann | Buy |
すべてを表示
Axogen Inc (AXGN) 最新ニュース
Can Axogen Inc. grow without external funding2025 Market Overview & Expert-Curated Trade Recommendations - classian.co.kr
Does Axogen Inc. fit your quant trading modelEntry Point & Advanced Technical Signal Analysis - Newser
Tools to assess Axogen Inc.’s risk profileMarket Weekly Review & Expert Curated Trade Ideas - Newser
Short interest data insights for Axogen Inc.Watch List & Fast Entry Momentum Alerts - Newser
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - MSN
Full technical analysis of Axogen Inc. stockWeekly Trade Review & High Win Rate Trade Alerts - Newser
How to read the order book for Axogen Inc.2025 Price Action Summary & Intraday High Probability Setup Alerts - Newser
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - MSN
Will Axogen Inc. outperform its industry peersTrade Risk Assessment & Weekly Breakout Stock Alerts - newsyoung.net
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth By Investing.com - Investing.com Nigeria
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com India
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
Axogen Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Weekly Recap & Community Shared Stock Ideas - metal.it
Axogen Inc. stock retracement – recovery analysis2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com Nigeria
Zurcher Kantonalbank Zurich Cantonalbank Invests $146,000 in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Leading vs lagging indicators on Axogen Inc. performanceTrade Alert System with Volume Analysis - Newser
How high can Axogen Inc. stock goSector Rotation Outlook With Historical Summary - Newser
Price momentum metrics for Axogen Inc. explainedFree Real Time Stock Movement Analysis - Newser
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FY2025 EPS Estimates for AxoGen Raised by Cantor Fitzgerald - Defense World
Is now a turning point for Axogen Inc.Market Forecast Summary Over Multi-Year Period - Newser
AxoGen (NASDAQ:AXGN) Upgraded to Buy at Wall Street Zen - Defense World
Can volume confirm reversal in Axogen Inc.Low Drawdown Picks with Weekly Updates - Newser
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - NewsBreak: Local News & Alerts
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
How to build a custom watchlist for Axogen Inc.Free Stock Selection With High Accuracy - Newser
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Risk adjusted return profile for Axogen Inc. analyzedRisk-Managed Swing Setup and Signal Analysis - Newser
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Jefferies raises AxoGen stock price target to $25 on strong sales growth By Investing.com - Investing.com South Africa
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Transcript : Axogen, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Axogen Boosts 2025 Revenue Growth Target to at Least 17% Ahead of BLA Approval. - AInvest
Axogen, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) - Seeking Alpha
Axogen Inc (AXGN) 財務データ
収益
当期純利益
現金流量
EPS
1.74%
0.24%
大文字化:
|
ボリューム (24 時間):